volume 381 pages 113562

Nanobody-based drug delivery systems for cancer therapy

Lin Liu 1, 2
Bin Tu 2, 3
Yao Sun 1, 2
Lingling Liao 1, 2
Xiaoling Lu 4
Ergang Liu 2
Yongzhuo Huang 1, 2, 3, 5, 6
Publication typeJournal Article
Publication date2025-05-01
scimago Q1
wos Q1
SJR2.470
CiteScore19.4
Impact factor11.5
ISSN01683659, 18734995
Abstract
Targeted delivery can elevate the local drug concentration within tumor tissues, while minimizing drug distribution to normal tissues, thus enhancing the effectiveness of anti-tumor medications and reducing adverse effects and systemic toxicities. Nanobodies, the novel molecular pattern of antibodies characterized by their small size, high stability, strong specificity, and low immunogenicity, have been extensively applied in targeted drug delivery for tumor therapy. This review discusses structural disparities and functional advantages of nanobodies compared to other antibody fragments and full-length antibody. It also highlights nanobody applications in targeted tumor therapy, focusing on their use in modifying delivery systems, e.g., liposomes, EVs, micelles, albumin nanoparticles, gold nanoparticles, polymeric nanoparticles, and as nanobody-drug conjugates. This review delves into the methods applied for integrating nanobodies into different drug delivery carriers, in order to provide useful information for researchers developing nanobody-based targeted drug delivery systems.
Found 
Found 

Top-30

Journals

1
ACS Applied Bio Materials
1 publication, 6.67%
Biotechnology Advances
1 publication, 6.67%
Drug Discovery Today
1 publication, 6.67%
ACS applied materials & interfaces
1 publication, 6.67%
Materials Research Express
1 publication, 6.67%
Cancer Treatment Reviews
1 publication, 6.67%
International Journal of Nanomedicine
1 publication, 6.67%
Nanoscale Horizons
1 publication, 6.67%
MedComm
1 publication, 6.67%
Chemical Engineering Journal
1 publication, 6.67%
Frontiers in Immunology
1 publication, 6.67%
Cancer Cell International
1 publication, 6.67%
Pharmaceutics
1 publication, 6.67%
Small Methods
1 publication, 6.67%
1

Publishers

1
2
3
4
5
Elsevier
5 publications, 33.33%
American Chemical Society (ACS)
2 publications, 13.33%
Wiley
2 publications, 13.33%
IOP Publishing
1 publication, 6.67%
Taylor & Francis
1 publication, 6.67%
Royal Society of Chemistry (RSC)
1 publication, 6.67%
Frontiers Media S.A.
1 publication, 6.67%
Springer Nature
1 publication, 6.67%
MDPI
1 publication, 6.67%
1
2
3
4
5
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
16
Share
Cite this
GOST |
Cite this
GOST Copy
Liu L. et al. Nanobody-based drug delivery systems for cancer therapy // Journal of Controlled Release. 2025. Vol. 381. p. 113562.
GOST all authors (up to 50) Copy
Liu L., Tu B., Sun Y., Liao L., Lu X., Liu E., Huang Y. Nanobody-based drug delivery systems for cancer therapy // Journal of Controlled Release. 2025. Vol. 381. p. 113562.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1016/j.jconrel.2025.02.058
UR - https://linkinghub.elsevier.com/retrieve/pii/S0168365925001713
TI - Nanobody-based drug delivery systems for cancer therapy
T2 - Journal of Controlled Release
AU - Liu, Lin
AU - Tu, Bin
AU - Sun, Yao
AU - Liao, Lingling
AU - Lu, Xiaoling
AU - Liu, Ergang
AU - Huang, Yongzhuo
PY - 2025
DA - 2025/05/01
PB - Elsevier
SP - 113562
VL - 381
SN - 0168-3659
SN - 1873-4995
ER -
BibTex
Cite this
BibTex (up to 50 authors) Copy
@article{2025_Liu,
author = {Lin Liu and Bin Tu and Yao Sun and Lingling Liao and Xiaoling Lu and Ergang Liu and Yongzhuo Huang},
title = {Nanobody-based drug delivery systems for cancer therapy},
journal = {Journal of Controlled Release},
year = {2025},
volume = {381},
publisher = {Elsevier},
month = {may},
url = {https://linkinghub.elsevier.com/retrieve/pii/S0168365925001713},
pages = {113562},
doi = {10.1016/j.jconrel.2025.02.058}
}